Bone Cancer

Bone Cancer, Second Edition comprehensively investigates key discoveries in the field of bone biology over the last five years that have led to the development of entirely new areas for investigation, such as therapies which combine surgery and biological approaches. The Second Edition expands on the original overview of bone cancer development (physiology and pathophysiology), with key chapters from the first edition, and offers numerous new chapters describing the new concepts of bone cancer biology and therapy, for both primary bone tumors as well as bone metastases. Each chapter has been written by internationally recognized specialists on the bone cancer microenvironment, bone metastases, osteoclast biology in bone cancer, proteomics, bone niche, circulating tumor cells, and clinical trials. Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for everyone within the medical and cancer research communities. Bone Cancer continues to offer the only translational reference to cover all aspects of primary bone cancer and bone metastases – from bench to bedside: development (cellular and molecular mechanisms), genomic and proteomic analyses, clinical analyses (histopathology, imaging, pain monitoring), as well as new therapeutic approaches and clinical trials for primary bone tumors and bone metastases. Presents a comprehensive, translational source for all aspects of primary bone cancer and bone metastases in one reference work Provides a common language for cancer researchers, bone biologists, oncologists, and radiologists to discuss bone tumors and how bone cancer metastases affects each major organ system Offers insights to research clinicians (oncologists and radiologists) into understanding the molecular basis of bone cancer, leading to more well-informed diagnoses and treatment of tumors and metastases Offers insights to bone biologists into how clinical observations and practices can feed back into the research cycle and, therefore, can contribute to the development of more targeted genomic and proteomic assays

Clear presentation by bone biologists of the cellular and molecular mechanisms underlying bone tumors and bone cancer metastasis as well as the genomic and proteomic assays used in detecting cancer within given organ systems Clear presentation by oncologists and radiologists of how histopathology, imaging, and pain monitoring can lead to new therapeutic approaches Benefit Saves researchers and clinicians time in quickly accessing the very latest details on a broad range of bone cancer issues, as opposed to searching through thousands of journal articles.-

Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside, Third Edition comprehensively investigates key discoveries in the field of bone biology. New aspects of bone cancer biology are treated in new chapters covering exosomes, autophagy, and metabolism. These have led to the development of entirely new areas for investigation, such as therapies which combine surgery and biological approaches. The Third Edition expands on the original overview of bone cancer development (physiology and pathophysiology), with 40% new material. Each chapter has been written by internationally recognized specialists on the bone cancer microenvironment, bone metastases, osteoclast biology in bone cancer, proteomics, bone niche, circulating tumor cells, and clinical trials. Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for everyone within the medical and cancer research communities. Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside continues to offer the only translational reference to cover all aspects of primary bone cancer and bone metastases. This revision opens the door to myeloma with two short chapters dedicated to this bone-associated disease. Covers the broad field of bone sarcomas and bone metastases from basic research to clinical approaches Presents comprehensive and translational overview of biological and clinical aspects of bone cancers, discussing pathophysiology from genetic and molecular levels using the most recent evidence Provides a common language for cancer researchers, bone biologists, oncologists, and radiologists to discuss bone tumors and how bone cancer metastases affects each major organ system Offers insights to research clinicians (oncologists and radiologists) into understanding the molecular basis of bone cancer, leading to more well-informed diagnoses and treatment of tumors and metastases Offers insights to bone biologists into how clinical observations and practices can feed back into the research cycle and, therefore, can contribute to the development of more targeted genomic and proteomic assays

Providing an integrated approach to the diagnosis and management of patients with metastatic bone disease (MBD), this comprehensive text combines discussion of the pathobiology of the disease with the latest oncological and orthopedic treatment modalities. After opening with an examination of the epidemiology and impact of MBD, the biology of bone metastases are discussed, along with considerations of the tissue of origin. Evaluation, biopsy and medical therapy, including metabolic agents and bio targeting. The heart of the book presents oncological approaches (supportive, radiation and interventional) and principles of orthopedic surgical oncology, with subsequent chapters covering specific anatomy, from the pelvis to the lower extremity and the spine. Chapters on emerging surgical technology and future directions conclude the text and redefine an integrated approach to patient care. Taken together, Metastatic Bone Disease is an excellent resource for orthopedic surgeons and cancer specialists alike.

PLEASE NOTE: Text has been accidentally deleted from page 54 of this book. Please refer to the corrigenda (PDF file) posted on the Stylus Publishing web site or email [email protected] for an updated, printable page. ****When not purchasing directly from the official sales agents of the WHO, especially at online bookshops, please note that there have been issues with counterfeited copies. Buy only from known sellers and if there are quality issues, please contact the seller for a refund.***** Soft Tissue and Bone Tumours is the third volume in the 5th edition of the WHO series on the classification of human tumours. This series (also known as the WHO Blue Books) is regarded as the gold standard for the diagnosis of tumours and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. These authoritative and concise reference books provide indispensable international standards for anyone involved in the care of patients with cancer or in cancer research, underpinning individual patient treatment as well as research into all aspects of cancer causation, prevention, therapy, and education. This volume will be of particular interest to pathologists, oncologists, surgeons, and epidemiologists who manage or research soft tissue and bone tumours. Sections are included on all recognized neoplasms of the soft tissue and bone, as well as on genetic tumour syndromes affecting these sites. Since the previous edition, there have been changes based on recent molecular and genetic information, with impact on clinical practice.

The American Joint Committee on Cancer's Cancer Staging Manual is used by physicians throughout the world to diagnose cancer and determine the extent to which cancer has progressed. All of the TNM staging information included in this Sixth Edition is uniform between the AJCC (American Joint Committee on Cancer) and the UICC (International Union Against Cancer). In addition to the information found in the Handbook, the Manual provides standardized data forms for each anatomic site, which can be utilized as permanent patient records, enabling clinicians and cancer research scientists to maintain consistency in evaluating the efficacy of diagnosis and treatment. The CD-ROM packaged with each Manual contains printable copies of each of the book’s 45 Staging Forms.

Hypercalcemia is the most common life-threatening metabolic disorder associated with cancer. The pathophysiological, epidemiological and clinical aspects of hypercalcemia of malignancy are presented in this issue, with a focus on the recently discovered humoral factor responsible for the development of hypercalcemia. With a better understanding of the pathophysiology of this condition and the development of new potent drugs, capable of inhibiting bone resorption, especially bisphosphonates, the clinician will be more successful in correcting hypercalcemia in the great majority of patients.

Bone and soft tissue sarcomas represent only about 2% of all malignancies; however, their treatment – with the goal of curing the patient while preserving the functionality of the affected body part – can, unlike other malignancies, only be successful with therapy concepts devised by interdisciplinary teams. This volume provides an extensive up-to-date overview of the specific diagnostics and current treatment standards of these rare entities, presenting the various limb-sparing modalities for patients with bone and soft tissue sarcomas with special regard to innovative reconstructive options. The evaluation of quality of life based on validated scores and the individual methods of coping with the illness through creative artistic projects are also acknowledged and integrated in the whole concept.